Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Melanoma vaccine forges ahead
Z?rich - Among skin cancer vaccines, Canvaxin (CancerVax Corp.) stands alone for reasons that include its unique profile of immunopotent antigens and its evidence for potential efficacy in extensive phase 2 testing. Perhaps more importantly, Canvaxin is currently the only skin cancer vaccine that's in large-scale phase 3 randomized postsurgical adjuvant trials for patients with stage 3 and 4 melanoma. These studies, if positive, will provide the necessary efficacy and safety data to support marketing approval.
Related Videos
Related Content
